Skip to Content

Did you know? Prevention and public health implications

Nov 2026

Did you know that GLP-1 medications cannot be considered as a form of primary prevention, as they treat existing obesity rather than addressing its underlying determinants? Instead, they may contribute to secondary and tertiary prevention by reducing the risk of obesity-related disease, although their longer-term population health impact remains uncertain.

Read more in our report Exploring the public health and equalities implications of GLP-1 obesity medications.

Did you know? Prevention and public health implications

pdf | 1.68MB

Download

Back to

Publications and resources